AT THE iQ GROUP GLOBAL,

That’s all we think about

We are a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.

Our scientific team identifies scientific discoveries from laboratories all over the world that have the potential to have life-changing impact.
Our corporate advisory and investment banking teams work together to translate scientific milestones into value creation events, creating financial instruments and corporate structures that activate commercial value.
Our commercialization team partners with healthcare providers and unlocks regulatory pathways to take the discovery to the people who need it.

The story so far

2019

The iQ Group Global acquires TEX Core, an oncology drug platform.
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine.
FarmaForce wins Sales Team of the Year at PRIME Awards for the third time.
Capital Labs raises more than $828,000 for healthcare startup.

2018

China patent granted for Saliva Glucose Biosensor.
FarmaForce wins Sales Team of the Year at PRIME Awards for the second time.

2017

US patent granted for Saliva Glucose Biosensor.

2016

The iQ Group Global accelerated the development of the Saliva Glucose Biosensor.
iQ Capital incorporated in the USA.
Series 8 Fund launched.
FarmaForce wins Sales Team of the Year at PRIME Awards.

2015

iQ3 ASX listed.
FarmaForce ASX listed.

2014

Inception of CRC and FarmaForce.

2013

iQX lists on NSX.
iQ3 inception.
OTFT-based saliva glucose biosensor invented by Professor Dastoor and team. IP filed in March.

2012

iQnovate commences trading in the USA.

2011

iQnovate lists on NSX.
iQX inception.

2010

Inception of iQnovate

Our Collaborators

Meet the people bringing our technology to life